Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Clinical Trial of RP832c in Scleroderma

Next Previous
Search
Trial Profile

Phase Ib Clinical Trial of RP832c in Scleroderma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUR 300 (Primary)
  • Indications Scleroderma
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Feb 2024 Status changed from planning to withdrawn prior to enrolment, according to an Aurinia Pharmaceuticals media release.
    • 15 Feb 2024 According to an Aurinia Pharmaceuticals media release, the company announced that effective immediately, the company will discontinue the development of AUR 300.
    • 03 Nov 2021 According to an Aurinia Pharmaceuticals media release, IND filing is expected during the first half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top